SHARE NOW
The Solupore® platform looks to accelerate the delivery of life-saving treatments to patients in need, by allowing the manufacture of next-generation cell therapies possessing superior cell health and functionality.
Cell engineering technology leader, Avectas, has announced their new non-viral cell-therapy manufacturing system, Solupore ®, is to be launched live at Phacilitate’s Advanced Therapies Week 2023, at Miami Beach Convention Centre (booth #331), from January, 17–20.
Solupore® is a non-viral delivery system that will allow the manufacture of next-generation cell therapies possessing superior cell health and functionality, to improve complex editing and difficult cargo delivery.
Built to provide easy integration into existing GMP processes, the Solupore® technology modifies cells by permeabilizing the target cell membrane to allow for molecular cargo delivery, while retaining high cell viability and functionality, therefore supporting therapeutic translation.
Ultimately Avectas’ Solupore® platform looks to accelerate the delivery of life-saving treatments to patients in need.
How are you enjoying this news article? Let us know your thoughts, here >>
“We have listened to the market and believe Solupore® is poised to address the current limitations of older transfection technologies for modifying therapeutic cells. Our system will seamlessly integrate into GMP processes to manufacture healthier and more functional cells,” explained Michael Maguire, CEO of Avectas.
Avectas is now set to offer on-site trials of the Solupore® system to customers and their molecular cargo, following a flexible commercial collaboration and licensing agreement. The technology is expected to be fully available, accompanied by full hands-on training across the workflow from Avectas, in H2 2023.
The Solupore® technology will join Avectas’ extensive data package based on therapeutic T cells, including complex editing, cell health, in vitro and in vivo, to which the Company is also in the process of adding IPS cells.
This launch follows the late 2022 announcement highlighting Avectas’ collaboration with Inceptor Bio to improve the manufacturing of CAR-T cell therapies targeting solid tumors.
“Launching our commercial system brings us closer to fulfilling our vision of working with partners to accelerate the future of cell therapies for patients,” Michael concluded.
Source: Avectas Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
